One Click Group Limited

1CG

One Click Group Ltd. engages in the provision of financial services. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2017-04-28. The principal activities of the Company include online taxation preparation (and other life administration) software and services in Australia, offering a range of other financial services. Its wholly owned subsidiary is Mobile Business Devices Pty Ltd.

Alterra Limited

1AG

Alterra Ltd. is a horticultural project developer, which focuses on the development of its Carpenters avocado project in Western Australia. The company is headquartered in Perth, Western Australia. The company went IPO on 2008-05-16. The firm is a developer of the Carpenters Avocado Project located between Manjimup and Pemberton in Western Australia’s south-west. The Carpenters Project consists of circa 100 hectares (ha) of Hass avocados. The Carpenters Project is a 200-hectare avocado development located near Pemberton, Western Australia, 3.5 hours south of Perth. Its Asset Management segment relates to the management of operating assets, including the contract to manage the demerged Carbon Business. Its Asset Development segment relates to assets owned or being developed by the Company. Its Business Development segment relates to the development of potential assets. The firm also holds a 15% direct interest in Carbon Conscious Investments Limited (CCIL), which manages large scale projects registered with the clean energy regulator that generate Australian Carbon Credit Units.

Algorae Pharmaceuticals Limited

1AI

Algorae Pharmaceuticals Ltd. is a biotechnology company, which engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. The firm is actively engaged in expanding its therapeutic pipeline using a proprietary artificial intelligence (AI) drug discovery and development platform, known as Algorae Operating System (AlgoraeOS). The AI platform leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. By employing machine learning, deep learning, and neural networks, the AlgoraeOS is focused on uncovering synergistic fixed dose drug combinations that lead to the development of effective treatments for any medical condition. The company is also focused on advancing its drug candidates, which include AI-116 for the treatment of neurodegenerative disorders and/or dementia, and AI-168 for cardiovascular disease and NTCELL for Parkinson’s disease.